Shai Kalansky focuses his practice on corporate and transactional matters, including mergers, acquisitions, venture capital financings, and securities offerings, for public and private companies. His clients are U.S. and non-U.S. entities in the high tech, consumer products, life sciences, and healthcare industries.
Mr. Kalansky represents both buyers and sellers in acquisitions and dispositions. He assists investors, public and private companies with a broad range of securities offerings, including venture capital financings, registered direct offerings, PIPE transactions and underwritten deals. He also acts as outside general counsel for companies in which capacity he advises clients with respect to licensing matters, commercial contracts and employment issues.
Mr. Kalansky is fluent in Hebrew and conversant in Spanish.
ACEA Biosciences, Inc.Represented ACEA Biosciences, Inc. in its US$250 million acquisition by Agilent Technologies Inc. (NYSE: A).
Cherokee Inc.’s Acquisition and Simultaneous Disposition of Hi-TecRepresented Cherokee in its acquisition of Hi-Tec Sports International Holdings B.V. and its simultaneous disposition of various operating assets in the United States, Canada, Europe and Africa.
Sale of California Cryobank to GI PartnersRepresented California Cryobank in its sale to GI Partners.
Sale of Abrams Artists AgencyRepresented Harry Abrams in the sale of Abrams Artists Agency.
Natel Engineering Company’s $280 million acquisition of OnCore ManufacturingRepresented Natel in its acquisition of OnCore Manufacturing.
Sale of BiotixRepresented the sellers of Biotix Holdings Inc. in their sale of all outstanding equity of Biotix to Mettler-Toledo, LLC.
Fulgent Genetics Initial Public OfferingRepresented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, as issuer’s counsel on its initial public offering.
Fulgent Genetics Preferred FinancingRepresented Fulgent Genetics, Inc. (NASDAQ: FLGT), a comprehensive genetic testing company, in its preferred stock financing of over $27 million.
Solarflare Communications, Inc. Preferred FinancingRepresented Solarflare Communications, Inc., a leading provider of application-intelligent networking I/O software and hardware, on numerous preferred stock financings totaling over $52 million.
Emerald Health Pharmaceuticals Regulation A+ OfferingRepresented Emerald Health Pharmaceuticals Inc., which is developing synthetic cannabinoid-derived drugs for CNS, autoimmune, and other diseases, in its Tier II Regulation A+ offering.
AMN Healthcare’s $160 million acquisition of B.E. SmithRepresented AMN in its acquisition of B.E. Smith.
AMN Healthcare’s $82 million acquisition of Onward HealthcareRepresented AMN in its acquisition of Onward Healthcare.
Sale of Mo Bio LaboratoriesRepresented the sellers of Mo Bio Laboratories in their sale of all outstanding equity of Mo Bio to Qiagen.
Netlist’s public offeringsRepresented Netlist (NASDAQ: NLST), a producer of next generation persistent memory solutions, in its public offerings of common stock and warrants.
Imprimis Pharmaceuticals, Inc. Acquisition of Compounding PharmacyRepresented Imprimis in its acquisition of South Coast Specialty Compounding, Inc.
Hitachi Metals, Ltd. LicensingRepresented Hitachi Metals, Ltd. in connection with patent license agreements and settlement agreements concluded in relation to an investigation at the U.S. International Trade Commission involving infringement of certain Hitachi Metals sintered rare earth magnet patents.
©1996-2019 Morrison & Foerster LLP. All rights reserved.